Advion Launches New Facility for Bioanalytical Services

Advion BioServices opens a new lab to satisfy increased demand for metabolism, ADME screening and other early-stage bioanalytical services.

Advion BioServices, a subsidiary of Advion BioSciences, Inc., has opened its new 22,000-sq.-ft. Drug Discovery and Metabolism bioanalytical lab in Indianapolis, IN. This expansion was in response to increased demand for metabolism, ADME screening and other early-stage bioanalytical services.

The new facility will focus on the earlier stage, drug discovery and metabolism bioanalytical services required for the preparation of a molecule’s entry into clinical testing. The site has approximately 50 employees.

"For our existing clients, the additional services offer a broader and more comprehensive approach to utilize early-access scientific knowledge and transfer this to later stage analysis,” said David B. Patteson, Advion’s president and chief executive officer.